Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||145917.93 g·mol−1|
|(what is this?)|
Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009[update], it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.
- WHO Drug Information
- Genentech: Rontalizumab (rhuMAb IFN alpha)
- Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
- Misra DP, Negi VS (March 2017). "Interferon targeted therapies in systemic lupus erythematosus". Mediterranean Journal of Rheumatology. 28 (1): 13–19. doi:10.31138/mjr.28.1.13. PMC 7045923. PMID 32185249.